Crisugabalin

Crisugabalin

SCHEMBL19982362

NC[C@@]1(CC(=O)O)[C@@H]2C[C@@H]3CC[C@H]1[C@H]2C3

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.35
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
BLM P54132 1/20 0.33
CACNA2D1 P54289 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD11B1 P28845 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Crisugabalin SCHEMBL28524348 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL19982340 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL19982295 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL21144566 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL24631233 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL21144567 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL23080519 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL23071142 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL23080592 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2
Crisugabalin SCHEMBL21621701 1.00 POLB (0.35) POLBUSP2ALDH1A1LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3527552-B1 FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFORE, AND MEDICAL USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) 2022-11-30 EP disclosed
EP-3527552-B1 FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFORE, AND MEDICAL USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) 2022-11-30 EP disclosed
WO-2021043117-A1 IMPURITY DETECTION METHOD FOR 2-((1S,2S,3R,6S,8S)-2-(AMINOMETHYL)TRICYCLO[4.2.1.0 3,8]NONANE-2-YL)ACETATE BENZENESULFONATE OR COMPOSITION THEREOF 四川海思科制药有限公司 2021-03-11 WO disclosed
US-10654794-B2 Fused tricyclic Γ-amino acid derivative, preparation method therefor, and medical use thereof SICHUAN HAISO PHARMACEUTICAL CO., LTD. (CN) 2020-05-19 US disclosed
US-20190218172-A1 FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF SICHUAN HAISO PHARMACEUTICAL CO., LTD. (CN) 2019-07-18 US disclosed
WO-2018050046-A1 FUSED TRICYCLIC Γ-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 四川海思科制药有限公司 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218172-A1 FUSED TRICYCLIC GAMMA-AMINO ACID DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF SLC38A7, BCAT2, SLC6A11 POLB 2881/4885USP2 4054/4885ALDH1A1 564/4885
US-10654794-B2 Fused tricyclic Γ-amino acid derivative, preparation method therefor, and medical use thereof SLC38A7, BCAT2, BCAT1 POLB 3130/4885USP2 4150/4885ALDH1A1 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.